Evidence map›Paper›PMID 42683071›Full record

ArticleERJ open research2026

SOLAR: a noninterventional study of outcomes over the long term of people with cystic fibrosis (CF) aged ≥6 years treated with elexacaftor/tezacaftor/ivacaftor using data from the French CF Registry.

Conor Daly, Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Carl A Baxter, Catherine Payen-Champenois, Olivier Giraudier, Heike Wohling, Pia Clara Pafundi, Antoine Bessou, Gabriela Vega-Hernandez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Conor DalyVertex Pharmaceuticals Incorporated, Boston, MA, USA.
Pierre-Régis BurgelFrench National Reference Cystic Fibrosis Center and Respiratory Medicine, Cochin Hospital, APHP, Paris, France.ORCID https://orcid.org/0000-0003-0903-9828
Isabelle Sermet-GaudelusERN Lung, Cystic Fibrosis Core Network, Frankfurt, Germany.
Carl A BaxterVertex Pharmaceuticals Incorporated, Boston, MA, USA.
Catherine Payen-ChampenoisVertex Pharmaceuticals Incorporated, Boston, MA, USA.
Olivier GiraudierVertex Pharmaceuticals Incorporated, Boston, MA, USA.
Heike WohlingVertex Pharmaceuticals Incorporated, Boston, MA, USA.
Pia Clara PafundiVertex Pharmaceuticals Incorporated, Boston, MA, USA.
Antoine BessouFrench CF Registry, Paris, France.
Gabriela Vega-HernandezVertex Pharmaceuticals Incorporated, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has demonstrated efficacy in people with cystic fibrosis (pwCF) aged ≥6 years with ≥1 Methods: Outcomes included per cent predicted forced expiratory volume in 1 s (ppFEV Results: The study included 553 pwCF aged 6-11 years, with a mean±sd age of 8.8±1.9 years at baseline, ppFEV Conclusion: This study confirms the longer term, transformational clinical benefit of ELX/TEZ/IVA in pwCF aged ≥6 years in a French population, demonstrating sustained improvements across multiple health outcomes, including in pwCF with ALD that were not part of the pivotal clinical trials.

Identifiers

PMID42683071
PMCPMC13531278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.